Brief: Pfizer Co & Astellas Announce Final Overall Survival Results From Phase 3 Embark Study For Xtandi In Combination With Leuprolide
19/10/2025 09:15
Oct 19 (Reuters) - Astellas Pharma Inc 4503.T: PFIZER: CO & ASTELLAS ANNOUNCE FINAL OVERALL SURVIVAL RESULTS FROM PHASE 3 EMBARK STUDY FOR XTANDI IN COMBINATION WITH LEUPROLIDE PFIZER: XTANDI PLUS LEUPROLIDE REDUCED RISK OF DEATH BY 40% VERSUS LEUPROLIDE ALONE IN MEN WITH A TYPE OF ADVANCED PROSTATE CANCER Source: https://tinyurl.com/tbbct8sw Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)